Drug
Gsk573719 Gw642444 Inhalation
Gsk573719 Gw642444 Inhalation: highest development phase Phase 3, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK573719/GW642444 Inhalation Powder NCT01376388 | Phase 3 | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow Gsk573719 Gw642444 Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.